First Time Loading...

Concert Pharmaceuticals Inc
NASDAQ:CNCE

Watchlist Manager
Concert Pharmaceuticals Inc Logo
Concert Pharmaceuticals Inc
NASDAQ:CNCE
Watchlist
Price: 8.37 USD Market Closed
Updated: Jun 3, 2024

Concert Pharmaceuticals Inc
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Concert Pharmaceuticals Inc
Cash Equivalents Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Concert Pharmaceuticals Inc
NASDAQ:CNCE
Cash Equivalents
$132.9m
CAGR 3-Years
142%
CAGR 5-Years
37%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash Equivalents
$18.1B
CAGR 3-Years
23%
CAGR 5-Years
30%
CAGR 10-Years
8%
Gilead Sciences Inc
NASDAQ:GILD
Cash Equivalents
$4.7B
CAGR 3-Years
5%
CAGR 5-Years
-23%
CAGR 10-Years
-3%
Amgen Inc
NASDAQ:AMGN
Cash Equivalents
$9.7B
CAGR 3-Years
17%
CAGR 5-Years
6%
CAGR 10-Years
10%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash Equivalents
$9.2B
CAGR 3-Years
13%
CAGR 5-Years
26%
CAGR 10-Years
36%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash Equivalents
$2.6B
CAGR 3-Years
22%
CAGR 5-Years
9%
CAGR 10-Years
19%

See Also

What is Concert Pharmaceuticals Inc's Cash Equivalents?
Cash Equivalents
132.9m USD

Based on the financial report for Dec 31, 2021, Concert Pharmaceuticals Inc's Cash Equivalents amounts to 132.9m USD.

What is Concert Pharmaceuticals Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
37%

Over the last year, the Cash Equivalents growth was 90%. The average annual Cash Equivalents growth rates for Concert Pharmaceuticals Inc have been 142% over the past three years , 37% over the past five years .